Grants.gov · synopsis:posted
Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)
- Verified from source 14 days ago
- Updated 24 days ago
- Amendment detected
- Agency
- National Institutes of Health
- Office
- HHS-NIH11
- Type
- synopsis:posted
- Kind
- grant
- Posted
- Jun 9, 2026
- Place
- —
- Notice ID
- 358991
- Source
- Grants.gov
- First seen
- Sep 6, 2026, 5:39 AM UTC
Full scope
The purpose of this notice of funding opportunity (NOFO) is to support innovative basic, clinical, translational, and implementation science research relevant to HIV and substance use. This initiative encourages high risk high impact transformative studies that advance knowledge and strategies for HIV prevention, diagnosis, treatment and virus suppression in people who use substances and/or have a substance use disorder.
Description
The purpose of this notice of funding opportunity (NOFO) is to support innovative basic, clinical, translational, and implementation science research relevant to HIV and substance use. This initiative encourages high risk high impact transformative studies that advance knowledge and strategies for HIV prevention, diagnosis, treatment and virus suppression in people who use substances and/or have a substance use disorder.
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Documents
- PAR-27-026-Revised-Full-Announcement.html Grants.gov access required
Contacts
-
National Institutes of Health
Related links
Full record synced 7 days ago from Grants.gov